Join
Live feed
·
PRReleasevia Quantisnow
Fractyl Health Inc. logo

Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation

ByQuantisnow·Wall Street's wire, on your screen.
GUTS· Fractyl Health Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GUTS (Fractyl Health Inc.) and more on Quantisnow.